NVAX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 82.81% compared to Novavax's net margin of 50.24%. Novavax's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

Novavax has a consensus price target of $14.67, signalling upside risk potential of 105.13%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 7.99%. Given that Novavax has higher upside potential than Johnson & Johnson, analysts believe Novavax is more attractive than Johnson & Johnson.

Novavax has a beta of 2.803, which suggesting that the stock is 180.302% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.2% to investors and pays a quarterly dividend of $1.30 per share. Novavax pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $626.3M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Novavax's net income of $518.6M is lower than Johnson & Johnson's net income of $11B. Notably, Novavax's price-to-earnings ratio is 2.70x while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.98x versus 4.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 82.81% compared to Novavax's net margin of 32.71%. Novavax's return on equity of -- beat Merck &'s return on equity of 39.02%.

Novavax has a consensus price target of $14.67, signalling upside risk potential of 105.13%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.4%. Given that Novavax has higher upside potential than Merck &, analysts believe Novavax is more attractive than Merck &.

Novavax has a beta of 2.803, which suggesting that the stock is 180.302% more volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.86% to investors and pays a quarterly dividend of $0.81 per share. Novavax pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $626.3M, which are smaller than Merck & quarterly revenues of $15.5B. Novavax's net income of $518.6M is lower than Merck &'s net income of $5.1B. Notably, Novavax's price-to-earnings ratio is 2.70x while Merck &'s PE ratio is 11.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.98x versus 3.25x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 82.81% compared to Novavax's net margin of -907.48%. Novavax's return on equity of -- beat Moderna's return on equity of -29.23%.

Novavax has a consensus price target of $14.67, signalling upside risk potential of 105.13%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 74.17%. Given that Novavax has higher upside potential than Moderna, analysts believe Novavax is more attractive than Moderna.

Novavax has a beta of 2.803, which suggesting that the stock is 180.302% more volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $626.3M, which are larger than Moderna quarterly revenues of $107M. Novavax's net income of $518.6M is higher than Moderna's net income of -$971M. Notably, Novavax's price-to-earnings ratio is 2.70x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.98x versus 3.39x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 82.81% compared to Novavax's net margin of 21.63%. Novavax's return on equity of -- beat Pfizer's return on equity of 8.72%.

Novavax has a consensus price target of $14.67, signalling upside risk potential of 105.13%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 17.71%. Given that Novavax has higher upside potential than Pfizer, analysts believe Novavax is more attractive than Pfizer.

Novavax has a beta of 2.803, which suggesting that the stock is 180.302% more volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.84% to investors and pays a quarterly dividend of $0.43 per share. Novavax pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Novavax quarterly revenues are $626.3M, which are smaller than Pfizer quarterly revenues of $13.7B. Novavax's net income of $518.6M is lower than Pfizer's net income of $3B. Notably, Novavax's price-to-earnings ratio is 2.70x while Pfizer's PE ratio is 18.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.98x versus 2.27x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.